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Abstract
An effective vaccine for the Human Immunodeficiency Virus (HIV) has been a global health priority for
decades. The HIV-1 surface protein Env is the sole envelope protein on the surface of the virus, presenting a
number of obstacles such as a carbohydrate coat on the surface of the protein and high variability in numerous
regions of the protein thereby rendering many traditional vaccine strategies ineffective. Here, a strategy to exploit
the variability in glycosylation among a limited number of non-essential yet conserved sites of Env has yielded
a hybrid protein consisting of an epitope from Env and a light-weight, thermally stable scaffold protein that may
function as an immunogen for HIV. The biophysical characterization of this engineered protein was attempted
computationally via molecular dynamics simulations and experimentally via circular dichroism and x-ray crystal-
lography to confirm the computational model and to evaluate the in vitro structure of the protein as well as the
fidelity of the epitope.
Introduction
The Human Immunodeficiency Virus (HIV) remains a global epidemic for decades, evading many attempts
at a working and lasting vaccine. HIV is a retrovirus which utilizes a membrane coated with a trimeric envelope
protein (Env) that functions in docking and entry of the host cell. The three subunits are heterodimers consisting
of gp41, a transmembrane protein embedded in the viral membrane that assists in trimerization and acts as a
membrane anchor, and gp120, which recognizes the transmembrane glycoprotein CD4 in conjunction with the
chemokine receptors CCR4 and CXCR5 on the host cell to mediate membrane fusion. As a result of this intimate
interaction with the host cell, the external surface of gp120 is the primary target for eliciting an immune response
such as neutralizing antibodies (NAbs), as well as the most conducive target in deriving man-made immunogens.1
Neutralizing antibodies are effective in fending off viral infection by negating the virus’s ability to infect the host
cell; for example, a neutralizing antibody for HIV may bind to the the CD4 binding domain on gp120, thereby
preventing the virus from docking and fusing to the cell membrane. However, the virus has several strategies to
mitigate the host immune response and likewise pose challenges in vaccine development. First, the surface of Env
is covered in a carbohydrate coat via N-linked glycosylation; this coat occludes most of the protein’s surface and
shields the majority of antigenic sites.2 Oftentimes, regions that would be ideal targets for conventional NAbs are
protected by heavy glycosylation in a pocket domain on gp120, such as the aformentioned CD4 binding domain.3
Env is also incredibly plastic and ever-changing, owing to its high variability in amino acid sequence among HIV
clades and a resulting variation in linked carbohydrates in a given population of viruses.4,5 The virus accomplishes
this with variable loops (referred to as V1-V5) that can withstand a high degree of change while still retaining the
protein’s original functionality. While NAbs may be produced in response to the initial infection, changes in these
variable regions will render these antibodies ineffective in the same time scale as producing those antibodies.6
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Lastly, Env exists in multiple metastable conformations that can only be stabilized by CD4 or other binders,
further complicating exploitation to elicit NAbs.
Despite these obstacles, there are several strategies being employed to create a vaccine. A popular strategy is to
induce broadly neutralizing antibodies (bNAbs) which recognize over 80 to 90% of viral strains. These bNAbs are
rare, however, occurring in a small percentage of individuals after 2-4 years of viral infection.7 These bNAbs only
target a select few antigen site on the Env complex, including the CD4 binding site and a conserved glycan site
among others. These bNAbs have some structural peculiarities that may grant them broadly neutralizing properties
including larger complementarity-determining regions and somatic modifications.8 A special method must be
employed to promote these sort of antibodies by promoting the correct B-cell pathway with the correct type of
immunogen at specific time points along the B cell maturation timeline. Figuring out the correct combination and
timing of booster immunogens may present another daunting obstacle in determining an effective vaccine method
comparable to those stated above.9
Seeking these bNAbs may be an extraneous task: instead of seeking to elicit a singular, broadly effective
immune response that could potentially be made ineffective by a singular or relatively few mutations in a viral
strain, a cocktail of immunogens which exploit numerous conserved epitopes on the gp120 could prove to be
more effective and resistant to mutation. The Dokholyan lab has made such a panel of engineered prototype
immunogens. These proteins consist of a light-weight, thermostable scaffolding protein with an antigen site from
HIV type 1 clade C gp120. Unlike many other approaches which target exposed regions of gp120, these antigen
site were sampled from the few regions which usually have a non-functional carbohydrate; in other words they
are Carboydrate Occluded Neutralizing Epitopes (CONEs). The key reason for choosing these counter-intuitive
targets stems from an analysis of a diverse panel of gp120 sequences by McCoy et al, suggesting 89% of HIV
strains are missing at least one conserved glycosylation site which would normally protect a specific antigenic
site.10 Moreover, it appears HIV in acutely infected individuals tend to be underglycosylated by about 4 positions
which were located in both variable and conserved regions. 11 This further evidences a potential target in regions
that are usually glycosylated since these regions tend to be more conserved than normally unprotected regions.
Thus, should a cocktail of these proteins be used as immunogens for clade C HIV, the likelihood of being rendered
ineffective by viral mutation is lower due to the non-universal selective pressure to do so per site.
Here, one such protein, named C1S1 because it consists of CONE number 1 on scaffolding protein number
1, is characterized structurally and thermodynamically both computationally and experimentally through a variety
of means. Since this protein was rationally designed for the purpose of being used as a potential vaccine, it
is important to check the structure experimentally and ensure that the design of the protein matches what was
intended and that the integrity of the antigenic site is kept in vitro. Moreover, it is just as important to examine
the stability and behavior of the protein in silico and in vitro to make sure the protein will not unfold at body
temperature or exhibit any sort of properties or peculiarities than can cause any aberrant interactions.
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Materials and Methods
Molecular Dynamics
Molecular dynamics simulations were ran on the C1S1 design structure three times using the Gromacs molec-
ular simulation package with the Charmm27 force field. Simulation boxes were solvated with the TIP3P model
of water and NaCl was added to a concentration of 150 mM. Simulation boxes were relaxed and equilibrated at
constant volume and temperature at 310 K for 100 ps in 50,000 step sizes, then constant pressure and temperature
at 1 atm and 310 K. Once equilibrated, the production molecular dynamics simulation were ran for 100 ns in
5×107 step sizes. RMSF data and b factor data were extracted from these trajectories and compared.
Protein Expression and Purification
The expression gene for C1S1 was inserted into a bacterial expression vector (pET 14b) and transformed in
the BL21 strain of Escherichia coli. A single colony was selected to inoculate 100 mL of LB medium containing
10 µg/mL ampicillin to grow overnight at 37 ◦C. From this culture, approximately 25 mL were aliquoted into two
to four 1L LB media containing 10 µg/mL ampicillin and grown to an OD600 of at least 0.60. Protein expression
was induced with IPTG to a final concentration of 1 mM for 3 hr at 37 ◦C. Cells were pelleted by centrifugation
at 5,000 g for 20 minutes. Pellets were frozen in -80 ◦C for storage.
For each round of purification via affinity chromatography, 2 bacterial pellets were thawed and resuspended
to a total volume of 60 mL using buffer A (20 mM PB, 100 mM NaCl, 40 mM imidizole, pH 7.4) with 20 µg
PMSF, 60 µg pepstain A, and 10 µl β-mercaptoethanol at approximately 4 ◦C. Cells were lysed via sonication
(40 minutes, 5 second bursts followed by 5 second rest) and centrifuged at 50,000 g for 20 minutes. Supernatant
was collected and passed through a 0.2 µm filter prior to purification via His-Tag nickel affinity chromatography.
The column was equilibrated with 30 mL of buffer A, loaded with the protein lysate, washed with buffer A, and
finally eluted on a gradient with buffer B (20 mM PB, 100 mM NaCl, and 500 mM imidizole at pH 7.4) ramping
to 90% in 40 minutes. Fractions were collected and stored in 4 ◦C for use in thermal denaturing studies or for
crystal screening.
Following affinity chromatography, samples were changed to SEC buffer (20 mM Tris and 500 mM NaCl at
pH 7.4). An analytical grade size exclusion column was equilibrated with 120 mL of SEC buffer. The sample was
injected and the peak corresponding to an unaggregated protein was collected. The fractions were combined and
the sample was concentrated down to a final volume of roughly 200 µl. Samples were flash frozen with liquid
nitrogen and stored in -80 ◦C.
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Thermally Denaturing Circular Dichroism
Protein samples were concentrated and changed to a buffer 60 mM PB buffer pH 7.4. Samples mean residue
ellipticity (MRE) from 190 to 260 nm were analyzed on a Chirascan Plus on a temperature ramp from 25 ◦C to 95
◦C. A melting curve was constructed by comparing the evolution of the MRE signal at 208 nm as the temperature
was increased.
Dialysis and Histidine Tag Cleavage
Following purification via His-Tag affinity chromatography, fractions containing C1S1 were concatenated
and dialyzed in TEV reaction buffer (50 mM Tris, 200 mM NaCl in 4 L at pH 8.0) for at least 4 hours prior
to cleaving at either 4 ◦C or 25 ◦C. Varying concentrations of TEV were added to samples at approximately a
1:100 TEV:C1S1 mass ratio and left to incubate for up to 4 days. Time point samples were taken for analysis via
SDS-PAGE (running at 1 hour at 200 V on 18% polyacrylamide gels).
Crystal Screening
A thawed protein sample following SEC at a concentration of 40 ng/µl was spun down at approximately 10,000
g to remove aggregates. The first round of crystal screening was conducted with a set of commercial screening
solutions via a Rigaku Phoenix crystal screening robot to set up a set of four 96 multiwell sitting drop trays. Drops
were monitored for up to 30 days at 20 ◦C for crystal hits. Two crystal hit conditions were selected for 24 well
optimization: 1. 20% w/v PEG 3050 and 100 mM NaOAc at pH 4.5; 2. 2 M Tris and 100 mM NaCl at pH 8.5.
Results
Protein Design
The hybrid protein C1S1 was designed by members of the Dokholyan laboratory using the in-house program
Eris. A motif mining algorithm developed in the Dokholyan laboratory was employed to search the Protein Data
Bank for lightweight, thermally stable scaffolding proteins that had structures that were similar to the selected
antigen region from gp120. The matched proteins had the corresponding structures mutated to the antigen site with
another in-house program, and the ∆∆Gmut were calculated. Largely destabilizing structures were thrown out
and a panel of stabilized or weakly destabilizing mutants were kept. A 10 amino acid antigen site originating from
the triple β-sheet on gp120 (named CONE 1) was grafted onto a similarly structured motif on the heterogeneous
nuclear ribonucleoprotein D0, or hnRNP (named Scaffold 1), to form C1S1.
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Figure 1: Side by Side Comparison of C1S1 and its Parent Scaffold The parent scaffold is shown on the left
and the engineered immunogen on the right.12 Residues shown in purple were replaced with residues shown in
cyan.
Molecular Dynamics
RMSF data and b factor visualization structures are shown in Figure 2. Overall, the scaffold appears to have
reasonably low fluctuations at around 1-2 A˚for all three simulations and structural variability with different grafted
epitopes including CONE 1. Note the frequent spike in RMSF at residues 35-40.
Figure 2: C1S1 MD Simulation Data Generated from Gromacs A. RMSF data generated from 3 Gromacs
simulations, shown in green, blue, and red. B. C1S1 structure with b factor spectrum representation; red denotes
residues with relatively high b factors, white for intermediate, and blue for relatively low.
Protein Expression
The target protein has been successfully expressed and purified numerous times. Typically for each batch
of C1S1 purified from 2L of induced E. coli, nickel column elution occurred at around 32% buffer B for an
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absorbance reading of about 800-1000 mAu; size exclusion purification for crystallization purposes typically in-
volved the concatenation of two batches of nickel column purified C1S1, and eluted at 103.433 mL for a peak
absorbance reading of about 800-1000 mAu. Size exclusion peaks suggest that C1S1 may exist in a two confor-
mations that cannot be separated by the column.
Histidine Tag Cleavage
TEV cleavage results do not appear to be conclusive. Multiple trials have been executed with different TEV
stocks for extended amounts of time to result in either partially cleaved protein (Figure 3A) or uncleaved protein
(Figure 3B). Interestingly, the partially cleaved protein from Figure 4A formed a hydrogel when concentrated.
This is a phenomenon commonly seen in nuclear RNA binding proteins which the scaffold for C1S1 belongs to.
Figure 3: SDS-PAGE Results for different TEV Protease Cleavage Experiments A. First TEV cleavage result,
with 4,6, and 9 hour time points at room temperature show partial cleavage. B. Another, later TEV cleavage, with
1, 2, and 4 day time points followed by a control for cold (left) and room temperature (right) experiments show
inconclusive results. Note 50% cleavage in A as opposed to what appears to be 0% cleavage in B.
Circular Dichroism
CD data (shown in Figure 4A) for both C1S1 and its parent scaffold protein display very similar curves,
suggesting close structural similarities between the two proteins in vitro. A melting curve from thermal denaturing
CD data is presented in Figure 4B. The melting point of the protein is about 57 ◦C. Results suggest C1S1 would
be stable at human body temperature at 37 ◦C with only about 5% of protein unfolded at this temperature in vitro.
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Figure 4: CD Spectra for C1S1 and Parent Protein with Melting Curves A. C1S1 and its parent protein share
similar structures in solution given the similarity of CD spectra. B. Melting curves built from CD spectra from 25
to 95 ◦C show C1S1 is slightly destabilized but still retains a high melting point.
Crystal Screening
Several hits (Figure 6) for C1S1 were found in 96 well screens using commercial reagents, summarized in
Table 1. Crystal hits, however, were often numerous, small, and irregularly formed, suggesting crystallization
would be a problem in the 24 well optimization by hanging drop. The two chosen conditions were expanded
with partially cleaved C1S1. Results showed at best very small, singular crystals at 10% w/v PEG 3050, 100 mM
NaOAc at pH 4.5 grown at 4 ◦C. Other wells showed aggregates forming almost immediately after adding protein
if a high concentration of crystallizing agent or salt was present in the drop.
Figure 5: Representative Crystals from Screening Conditions Screening crystals for 10% w/v PEG 3050, 100
mM NaOAc at pH 4.5. Screening well for scale, drop is approximately 1µL. Note small size and malformed
shape.
Table 1: Crystal Screening Conditions The first two entries were expanded in 24 well hanging drop experiments
Crystallizing Agent/Organic Solvent Buffer (pH) Salt
20% w/v PEG 3350 100 mM NaOAC (pH 4.5) –
– 2 M Tris (pH 8.5) 100 mM NaCl
30 % w/v glycerol; 14% v/v 2-propanol – 140 mM CaCl2; 70 mM NaCl
2% w/v PEG 8,000 – 500 mM Li2SO4
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Discussion
C1S1 Design Is Thermostable and Retains Shape at Body Temperature
RMSF data presented in Figure 2 shows that epitope sites have a RMSF of around 1 A˚. However, the b factor
around some sites are rather high b factor values, which are a measure of uncertainty in electron density: this
high disorder can be attributed to the rather long side chains with displaced electrons at these positions, such as
histidine and asparagine at positions 28 and 30, respectively. CD spectra for C1S1 and the parent scaffold are
rather similar, suggesting that they share structural characteristics and likely have the same general shape. The
melting curve for C1S1 built from the CD signal at 208 nm (α helix) show that C1S1 is slightly destabilized
compared to the parent protein but still retains structure at 37◦. Both computational and experimental data suggest
the native structure that C1S1 adopts is thermostable, has low disorder at epitope sites, and assumes the overall
shape of its parent scaffold. Designing a thermostable immunogen that retains shape at elevated temperatures is
important in ensuring that the epitope of interest is being introduced to the immune system. If the protein readily
unfolds at 37 ◦C then any sort of immune response elicited by introducing the defective immunogen will not be
able to recognize any version of gp120.
C1S1 Contains Disordered Regions That May Inhibit Crystallization
Although some crystal hits were identified during crystal screening, no harvestable crystals could be collected
for x-ray diffraction. A possible explanation for the poor and unreliable crystal formation can be found in b factor
and RMSF data from molecular dynamic simulations, which suggest that the protein contains some regions with
large fluctuations. These unstructured regions on the surface of globular proteins can impede the protein’s ability
to crystallize due to a higher entropic barrier requirement in immobilizing these disordered side chains for the
sake of packing with other proteins. According to Price et al, there are certain residues which exhibit high side
chain entropy that strongly anti-correlate with successful crystallization should they reside on the surface of the
protein, namely glutamine, tyrosine, asparagine, glutamic acid, and lysine. C1S1 contains many of these residues
on its surface which also tend to have the largest B factors in the protein, particularly lysine.13 It may be possible
to edit some of these high disorder residues to one with low entropy side chains for crystallization, although this
may completely change the structure of the protein in unpredictable ways.
C1S1 May Retain Properties Associated hnRNPs Such as Forming Hydrogels
Interestingly, upon partially cleaving a concentrated sample (approx. 2L worth) of C1S1 with TEV, protein
aggregates started to form while dialyzing for an extended period of time at room temperature. This behavior is
an abnormality for C1S1, as uncut samples of C1S1 have been concentrated to greater extents and dialyzed for
just as long without showing any signs of aggregation; thus, this may be a behavior exclusive to C1S1 where a
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significant portion ( 50%) has the His-Tag cleaved. Concentrating the sample even further and centrifuging at
10,000 g resulted in a hydrogel phase at the bottom of the tube. This phase has not been extensively studied for
C1S1, however it is important to note that C1S1’s parent scaffold is a type of heterogeneous nuclear RNA binding
(hnRNP) protein. According to Hughes, these proteins–among others–contain ”low-complexity, aromatic rich
kinked segments” (LARKS) which tend to stack to form fibril structures. LARKS have three shared characteristics
among them: high solubility due to the presence of asparagine, glutamine, and serine; backbone flexibility afforded
by glycine; and interaction motifs, particularly due to aromatic residues.14 C1S1 has several such motifs, namely
residues 19-24, YFSKFG, and 42-49, GEGVVTFK–the former of which resides on an α helix and the latter on
a β strand according to the design model. These motifs present on C1S1 may explain the described behavior if
cutting the His-Tag off the protein allowed for interactions between these LARKS to take place, stack into fibrils,
and form a hydrogel. The conditions must first be repeated and examined with, for example, electron microscopy
in order to confirm that such is actually taking place. Nevertheless, while attaining the required concentration is
unlikely to happen if C1S1 were to be used as an immunogen, it would be interesting to see if these properties
result in C1S1 nucleating a phase separation event with other proteins.
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